Biologic therapies have proven efficacious for patients with moderate-to-severe psoriasis. However, their economic value compared with standard of care in Italy has not been explored. This study estimates the cost-effectiveness of intermittent therapy with etanercept in patients with moderate-to-severe plaque-type psoriasis in comparison with nonsystemic therapy in Italy.

Colombo, G., Di Matteo, S., Peris, K., Fargnoli, M., Esposito, M., Mazzotta, A., Chimenti, S., A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy, <<CLINICOECONOMICS AND OUTCOMES RESEARCH>>, 2009; 1 (Ottobre): 53-59 [http://hdl.handle.net/10807/57495]

A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy

Peris, Ketty;
2009

Abstract

Biologic therapies have proven efficacious for patients with moderate-to-severe psoriasis. However, their economic value compared with standard of care in Italy has not been explored. This study estimates the cost-effectiveness of intermittent therapy with etanercept in patients with moderate-to-severe plaque-type psoriasis in comparison with nonsystemic therapy in Italy.
2009
Inglese
Colombo, G., Di Matteo, S., Peris, K., Fargnoli, M., Esposito, M., Mazzotta, A., Chimenti, S., A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy, <<CLINICOECONOMICS AND OUTCOMES RESEARCH>>, 2009; 1 (Ottobre): 53-59 [http://hdl.handle.net/10807/57495]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/57495
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact